Receptor Tyrosine Kinase Inhibitory Activities and Molecular Docking Studies of Some Pyrrolo[2, 3-d]pyrimidine Derivatives Receptor tyrosine kinase inhibitory effects of some pyrrolopyrimidine derivatives
Iranian Journal of Pharmaceutical Sciences,
Vol. 15 No. 4 (2019),
1 October 2019
,
Page 73-82
https://doi.org/10.22037/ijps.v15.40465
Abstract
In this study, we aimed to determine VEGFR-2, EGFR and PDGFR-β tyrosine kinase inhibitory activities of some pyrrolo[2,3-d]pyrimidine derivatives previously synthesized and showed potent cytotoxic and apoptotic effects against several cancer cell lines by our group and to evaluate the relationships between inhibitory activities and binding properties of the active compounds by molecular docking studies. VEGFR-2, EGFR ve PDGFR-β tyrosine kinases inhibitory activities of the tested compounds were determined using KDR Kinase Enzyme System Analysis Kit (Promega, #V2681), EGFR Kinase Enzyme System Analysis Kit (Promega,#V3831) and PDGFR-β Kinase Enzyme System Analysis Kits (Promega, #V3731) according to the manufacturer’s instructions. The molecular docking studies were performed using Autodock vina program.Compounds 9a, 9b and 11b exhibited the weak inhibitory activities against VEGFR-2, EGFR and PDGFR-β,respectively. Molecular docking studies showed that one or two hydrogen bonding interactions were found between compounds 9a, 9b, 11b and VEGFR-2, EGFR, PDGFR-β tyrosine kinases. Biological activity and molecular docking results revealed that interactions of compounds with target protein active sites are not enough to obtain potent RTK inhibitory activity. It is necessary to design some compounds showing more interactions with the target proteins to obtain better activity results.
- Receptor tyrosine kinases inhibitors
- pyrrolo[2,3-d]pyrimidines
- molecular docking
How to Cite
References
(2016) 16: 62-70.
[2] Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem. Sci. (2014) 39: 465-474.
[3] Brunelleschi S, Penengo L, Santoro MM, et al.Receptor tyrosine kinases as target for anti-cancer therapy. Curr. Pharm. Des. (2002) 8 (22): 1959-1972.
[4] Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer (2004) 90:2250-2255.
[5] Roskoski R. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys.Res. Commun. (2008) 375: 287-291.
[6] Subramanian J, Morgensztern D, Govindan R.Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin.Lung Cancer (2010) 11: 311-319.
[7] Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. Cytokine & Growth Factor Rev. (2016) 28:53-61.
[8] Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Rev.(2009) 9: 28-39.
[9] Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol.Sci. (2015) 36: 422-439.
[10] Gao H, Su P, Shi Y, et al. Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime. Eur. J. Med.Chem. (2015) 90: 232-40.
[11] Wang C, Gao H, Dong J, et al. Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation.Bioorg. Med. Chem. (2014) 22:277-84.
[12] Mohammadi M, Froum S, Hamby JM, et al.Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. The EMBO J. (1998) 17: 5896-5904.
[13] Dai Y, Hartandi K, Ji Z, et al. Discovery of N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N’-(2-fluoro-5-methylphenyl) urea (ABT-869), a 3-aminoindazolebased orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem. (2007) 50: 1584-1597.
[14] Beebe JS, Jani JP, Knauth E, et al.Pharmacological characterization of cp-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. (2003) 63: 7301-7309.
[15] De Coen LM, Heugebaert TSA, García D, et al.Synthetic entries to and biological activity of pyrrolopyrimidines. Chem. Rev. (2016) 116: 80-139.
[16] Traxler P, Allegrini PR, Brandt R, et al. AEE788:a dual family epidermal growth factor receptor/erbb2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and
antiangiogenic activity. Cancer Res. (2004) 64: 4931-4941.
[17] Hoekstra R, Dumez H, Eskens FALM, et al.Phase I and pharmacologic study of PKI-166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. (2005) 11: 6908-6915.
[18] Gangjee A, Yang J, Ihnat MA, et al.Antiangiogenic and antitumor agents: design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. Bioorg. Med. Chem. (2003) 11:5155-5170.
[19] Oguro Y, Miyamoto N, Takagi T, et al. NPhenyl-N’-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases. Bioorg. Med. Chem. (2010) 18:7150-7163.
[20] Kilic-Kurt Z, Bakar-Ates F, Karakas B et al.Cytotoxic and apoptotic effects of novel pyrrolo[2,3-d]pyrimidine derivatives containing urea moieties on cancer cell lines. Anticancer Agents Med. Chem.(2018) 18: 1303-1312.
[21] Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838-4848.
[22] Roskoski R. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.Biochem. Biophys. Res. Commun. (2007) 356: 323-328.
[23] Rani UP, Kesavan R, Ganugula R, et al. Ellagic acid inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and prevents atheroma formation in streptozotocin-induced diabetic rats. J.Nutr. Biochem. (2013) 24: 1830-1839.
- Abstract Viewed: 412 times
- IJPS_Volume 15_Issue 4_Pages 73-82 Downloaded: 405 times